August 25, 2022
Eisai said on August 24 that its US subsidiary Eisai Inc. has entered into a memorandum of understanding (MOU) with Missouri-headquartered C 2 N Diagnostics, a diagnostics specialist for cognitive impairment including Alzheimer’s Disease (AD). Under the MOU, the companies...read more